uniQure NV (QURE) Shares Down 1.5%
Shares of uniQure NV (NASDAQ:QURE) fell 1.5% during mid-day trading on Friday . The company traded as low as $7.22 and last traded at $7.26, with a volume of 96,100 shares changing hands. The stock had previously closed at $7.37.
A number of research firms have recently issued reports on QURE. Jefferies Group reiterated a “buy” rating on shares of uniQure NV in a report on Tuesday, May 31st. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of uniQure NV in a report on Tuesday, May 31st. Chardan Capital reiterated a “buy” rating on shares of uniQure NV in a report on Thursday, April 14th. Leerink Swann reiterated a “buy” rating and issued a $27.00 price objective (down from $48.00) on shares of uniQure NV in a report on Wednesday, April 13th. Finally, Piper Jaffray Cos. reiterated a “buy” rating on shares of uniQure NV in a report on Monday, June 13th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $30.80.
The company’s market capitalization is $177.95 million. The company has a 50-day moving average price of $8.75 and a 200-day moving average price of $12.69.
uniQure NV (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, May 31st. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by $0.10. Equities analysts predict that uniQure NV will post ($3.14) EPS for the current year.
Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.